# EMERALD-3 (NCT05301842)

> Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05301842
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Hepatocellular Carcinoma
- Interventions: Tremelimumab; Durvalumab; Transarterial Chemoembolization (TACE); Lenvatinib
- Enrollment: 760
- Primary outcome: Progression Free Survival (PFS) for Arm A vs Arm C

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 70
- YouTube: 33
- Podcasts: 20
- Bluesky threads: 3
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=emerald-3-nct05301842

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05301842", "email": "<work email>"}; the inbox owner confirms by the emailed link.